NEDD4 regulates VEGF signaling and mTOR to promote angiogenesis and the cell cycle in steroid‑induced osteonecrosis of the femoral head

Nov 21, 2025Molecular medicine reports

NEDD4 supports new blood vessel growth and cell division by controlling VEGF and mTOR in steroid-related bone tissue death in the hip

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

The E3 ubiquitin ligase NEDD4 is implicated in steroid-induced osteonecrosis of the femoral head, affecting cell viability and angiogenesis.

Ubiquitination is associated with the development of steroid-induced osteonecrosis of the femoral head.
NEDD4 correlates positively with genes involved in the p53 signaling pathway, DNA damage response, and cell cycle regulation.
NEDD4 overexpression enhances the viability, migration, and angiogenesis of bone microvascular endothelial cells.
Higher mRNA levels of mTOR, VEGF, and VEGFR2 are observed in NEDD4-overexpressing cells, indicating activation of the VEGF signaling pathway.
NEDD4 may indirectly modulate mTOR ubiquitination, as shown by decreased mTOR ubiquitination levels following its overexpression.
Glucocorticoids are linked to suppressed NEDD4 expression through increased promoter methylation levels.

AI simplified

Steroid‑induced osteonecrosis of the femoral head (SONFH) is a progressive hip condition marked by osteocyte apoptosis from poor blood supply, leading to femoral head collapse and hip joint dysfunction. Examination of the GSE123568 dataset revealed the important role of ubiquitination in the development of SONFH, contributing to processes such as 'apoptosis', 'protein processing in the endoplasmic reticulum', 'lysosome function', 'cell cycle regulation and autophagy'. The present research revealed that the E3 ubiquitin ligase neural precursor cell expressed developmentally downregulated protein 4 (NEDD4) is involved in SONFH, showing positive correlations with key genes in the p53 signaling pathway, DNA damage response and cell cycle regulation. This highlights the role of NEDD4 in DNA repair and cell cycle control. Additionally, NEDD4 exhibited varying regulatory effects on integrin, TGF‑β/SMAD, Hippo/yes‑associated protein and Notch signaling pathways, underscoring its multifaceted role in cellular signaling. A NEDD4 overexpression vector was created and found to significantly boost the viability, migration and angiogenesis of bone microvascular endothelial cells (BMECs). Reverse transcription‑quantitative PCR results revealed higher mRNA levels of mTOR, VEGF and VEGFR2 in NEDD4‑overexpressing cells, suggesting that the VEGF signaling pathway was activated. Immunoprecipitation assays showed decreased mTOR ubiquitination levels following NEDD4 overexpression, suggesting NEDD4 may indirectly modulate mTOR ubiquitination rather than directly catalyzing it., Small interfering RNA experiments found that NEDD4 and mTOR cooperated to boost BMEC proliferation and migration, as confirmed by MTT, EdU and wound healing assays. Furthermore, the present research showed that glucocorticoids could suppress NEDD4 expression by increasing promoter methylation levels. These findings highlight the key roles of NEDD4 in angiogenesis, maintaining cell balance, regulating the cell cycle and repairing DNA damage in SONFH. By demonstrating the numerous functions of NEDD4 in steroid‑induced osteonecrosis and angiogenesis, the present study suggested that it may impact vascular growth and bone tissue repair through multiple pathways and mechanisms.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View on DOI ↗View on PubMed ↗

NEDD4 regulates VEGF signaling and mTOR to promote angiogenesis and the cell cycle in steroid‑induced osteonecrosis of the femoral head

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief